Germany's health insured prepare for future cut-backs in services and products:
This article was originally published in Clinica
Executive Summary
Nine out ten of those insured under Germany's statutory health insurance system expect that they will not have access to a complete range of healthcare options in the future. That is one of the findings of the latest biannual survey by the Bertelsmann Foundation. The privately-insured are less pessimistic, but still 62% of those payers believe that their access to healthcare will be subject to stricter controls in the future. In addition, 81% of public and 67% of private patients see waiting lists for treatment lengthening, something which has traditionally not been a feature in German healthcare, while other countries, such as the UK, have routinely laboured under such conditions. The survey also showed that some 8% of public patient requests for prescriptions were turned down, while only a minor portion in the private sector were (three out of 216 respondents). The healthcare reform has changed the landscape for German healthcare, where out-of-pocket payments are becoming much more enshrined, while statutory sickness funds start to record surpluses once more. A total of 1, 539 people were surveyed.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.